First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

<strong>Background</strong> Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom...

Full description

Bibliographic Details
Main Authors:	Tiono, AB, Nebie, I, Anagnostou, N, Coulibaly, AS, Bowyer, G, Lam, E, Bougouma, EC, Ouedraogo, A, Yaro, JBB, Barry, A, Roberts, R, Rampling, T, Bliss, C, Hodgson, S, Lawrie, A, Imoukhuede, EB, Ewer, KJ, Viebig, NK, Diarra, A, Leroy, O, Bejon, P, Hill, A, Sirima, SB
Format:	Journal article
Published:	Public Library of Science 2018

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Similar Items